Compare M&T Bank Corporation (MTB) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs Travere Therapeutics Inc. Common Stock — how do they compare? M&T Bank Corporation trades at $215.86 (market cap $31.47B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: M&T Bank Corporation is far larger — about 6.4× Travere Therapeutics Inc. Common Stock's market cap, and M&T Bank Corporation pays a 2.75% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold M&T Bank Corporation for 99 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MTB | TVTX | |
|---|---|---|
Market Cap | $31.47B | $4.88B |
Volume | 743,357 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $254.09 | $67.52 |
52-Week Low | $178.63 | $26.79 |
Typical Hold Time | 99 Days | 0 Days |
Enterprise Value | $47.83B | $5.01B |
Dividend Yield | 2.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank Corporation (MTB) trades at $216.05, down 1.75% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026), a P/E of 11.54, and net income margin of 30.85%. Recent developments include a new Connecticut branch opening and AI investments to drive loan growth. Cash flow trends show operational strength despite negative net cash flow in 2025.
MTB presents a value opportunity with attractive valuation metrics and dividend stability, though technical weakness and competitive banking pressures pose near-term risks. Analyst consensus targets $258.92 (19.8% upside) with 31% buy ratings, but investors should monitor loan growth execution and interest rate sensitivity.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
